FDA Confirms Approach to Sofdra NDA Resubmission
Filed with ASX · · 2 pages · English
Watch Botanix Pharmaceuticals' latest callBotanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call · Replay · Mar 2Read the transcript of Botanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings CallBotanix Pharmaceuticals Limited on 6ix
Earlier from Botanix Pharmaceuticals
- Successful Completion of $13.5m Institutional Placement
- Botanix Placement Secures $13.5M to Fund Sofdra Launch Prep
- Investor Presentation and Investor Meetings
- September 2023 Quarterly Activities Report and Appendix 4C
- Presentation- FDA Letter Requires Patient Instruction Update
Later from Botanix Pharmaceuticals
- Successful Completion of Human Factors Study
- Botanix Resubmission of NDA for Sofdra Completed
- NDA Resubmission Accepted and Approval Date Confirmed
- December 2023 Quarterly Activities Report and Appendix 4C
- Botanix Pharmaceuticals Half Year Report
Follow Botanix Pharmaceuticals into a list and get an email when it puts out news.
Follow Botanix Pharmaceuticals